8-K: Synaptogenix Pivots to AI Crypto Treasury Strategy with $5.5 Million Financing and Key Leadership Changes

Synaptogenix, Inc. announced a $5.5 million private placement to fund a new cryptocurrency treasury strategy focused on Bittensor TAO, alongside significant executive leadership changes.

Summary

• Synaptogenix, Inc. (SNPX) entered into a Securities Purchase Agreement on June 9, 2025, for a private placement expected to close on June 10, 2025.
• The private placement involves the sale of 5,500 shares of newly designated Series D convertible preferred stock (stated value $1,000 per share) and warrants to purchase up to 1,833,333 shares of common stock.
• The aggregate gross proceeds from the private placement are expected to be $5.5 million.
• Net proceeds will be used for general corporate purposes and working capital, including the initial acquisition of $10 million of Bittensor TAO tokens, with a total acquisition target of $100 million.
• The company is launching a differentiated cryptocurrency treasury strategy focused exclusively on Bittensor TAO, identified as the leading AI token by market capitalization and adoption.
• James Altucher and Z-List Media, Inc. have been engaged as consultants, effective June 8, 2025, for one year, to assist with crypto portfolio management, investor relations, strategic planning, and deal flow analysis related to sector growth initiatives.
• As part of the consulting agreement, James Altucher received warrants to purchase 1,200,000 shares of common stock at exercise prices ranging from $4.00 to $12.00, with varying vesting schedules.
• Dr. Daniel L. Alkon resigned as an officer, director, and Chief Science Officer on June 4, 2025, transitioning to a consultant role as Director of the Bryostatin Platform Development Program with a reduced monthly salary of $12,500.
• Dr. Alan J. Tuchman resigned as Chief Executive Officer and director on June 8, 2025, and will now serve as Chief Medical Officer with a reduced monthly salary of $7,500.
• Joshua Silverman was appointed Executive Chairman of the Board of Directors on June 6, 2025, with a monthly salary of $30,000.
• The company intends to change its name and ticker symbol in accordance with its new digital asset treasury strategy.

Sentiment

Score: 6

Explanation: The sentiment is cautiously positive. While the capital raise provides necessary funding and the strategic pivot into AI crypto is ambitious and could offer significant upside, it also introduces substantial new risks associated with cryptocurrency volatility, regulatory uncertainty, and concentration risk. The management changes align with the new strategy, but the shift away from the previous core business (Bryostatin) is a major change. The potential for high returns is balanced by high risk.

Positives

• Successful capital raise of $5.5 million, providing funds for general corporate purposes and a new strategic initiative.
• Engagement of James Altucher, a recognized expert in AI and cryptocurrency, to lead the new digital asset treasury strategy.
• Strategic pivot towards the rapidly growing artificial intelligence (AI) and cryptocurrency sectors, specifically focusing on Bittensor TAO, which is highlighted as a leading AI token.
• Potential for significant shareholder value creation through TAO token appreciation and staking yield, with a target acquisition of $100 million in TAO tokens.
• Restructuring of management roles to align with the new strategic direction, including the appointment of an Executive Chairman.

Negatives

• Significant shift in business strategy from pharmaceutical development (Bryostatin) to cryptocurrency treasury management, which may introduce new and different risks.
• The new strategy focuses on a single cryptocurrency (Bittensor TAO), concentrating risk.
• The terms of the Series D preferred stock include a 5% annual dividend (compounded quarterly) and a 15% default dividend rate, which could be costly.
• The preferred stock redemption is at 107% of the installment amount, indicating a premium payment.
• Warrants issued to investors and consultants could lead to significant dilution if exercised, especially with price-based adjustments (full ratchet) for investor warrants.
• The company is required to seek stockholder approval for issuing more than 19.99% of outstanding common stock, which could delay full conversion/exercise of the new securities.
• The company's previous core business (Bryostatin assets) appears to be de-emphasized, with the former CSO transitioning to a consultant role for this program.

Risks

• Market Volatility: The value of Bittensor TAO tokens is subject to significant volatility inherent in cryptocurrency markets, which could lead to substantial losses.
• Regulatory Uncertainty: The cryptocurrency market faces evolving and uncertain regulatory environments, which could impact the legality or profitability of the company's digital asset treasury strategy.
• Concentration Risk: The strategy's exclusive focus on a single asset (Bittensor TAO) exposes the company to risks specific to that token and its underlying network.
• Execution Risk: The success of the new strategy depends on the effective management of crypto assets and the ability to generate staking yield and token appreciation, which is speculative.
• Shareholder Dilution: The conversion of preferred stock and exercise of warrants could lead to substantial dilution of existing common stock shareholders, especially given the price-based adjustments.
• Nasdaq Listing Compliance: The company needs to obtain Nasdaq Stockholder Approval by September 1, 2025, to issue more than 19.99% of its outstanding common stock, and failure to do so could limit conversions or exercises.
• Liquidity Risk: There is no established public trading market for the Series D Preferred Stock or the Warrants, which limits their liquidity.
• Financial Covenants: The company is subject to various financial and operational covenants under the preferred stock terms, including maintaining a minimum cash balance of $5.5 million, and breaches could trigger redemption at a premium.
• Litigation/Regulatory Scrutiny: Engaging in cryptocurrency activities may attract increased scrutiny from regulatory bodies.

Future Outlook

Synaptogenix plans a significant strategic pivot towards a digital asset treasury strategy, focusing exclusively on acquiring Bittensor TAO tokens, with an initial target of $10 million and a long-term goal of $100 million. This strategy aims to generate revenue through staking yield and token appreciation. The company intends to change its name and ticker symbol to reflect this new direction and is developing a new corporate website. Shareholder approval will be sought by September 1, 2025, for the issuance of common stock exceeding Nasdaq's 19.99% limit.

Management Comments

• "Near the end of 2024, our Board of Directors began exploring value creation opportunities to best utilize our significant cash reserves."
• "We have witnessed an increasing number of public and private companies allocate digital assets to their corporate treasuries successfully or use them as part of their business strategies."
• "We believe the leading AI token, TAO, offers the best outlook for growth and adoption as well as the best opportunity to create and preserve value for our stockholders."
• "We are fortunate to bring on James Altucher, a world-class authority on both AI and crypto, to drive revenue generation and TAO staking strategies in pursuit of significantly increasing shareholder value."
• "Based on our initial review, we believe the fixed market supply of 21 million TAO tokens alongside rapidly increasing global demand for AI development and adaptation makes TAO a compelling cryptocurrency."
• "The AI industry is expected to grow tenfold between now and 2030, and some percentage of every dollar allocated to AI is expected to go towards decentralized AI where TAO is the clear leader."
• "I am excited to be a part of what I believe is the only pure play public company focused on the convergence between crypto and AI as both industries continue to grow exponentially."

Industry Context

This announcement reflects a growing trend of companies exploring digital assets for treasury management and strategic business initiatives, particularly within the burgeoning artificial intelligence (AI) and cryptocurrency convergence space. By focusing on Bittensor TAO, Synaptogenix is targeting a specific niche within decentralized AI, aiming to capitalize on the anticipated exponential growth of the AI industry and the increasing adoption of AI-focused crypto tokens. The move positions Synaptogenix as a "pure play" public company at the intersection of crypto and AI, a relatively novel approach for a publicly traded entity.

Management Changes

Corporate Governance

Related Party Transactions

• James Altucher and Z-List Media, Inc. entered into a consulting agreement with the Company, receiving warrants to purchase 1,200,000 shares of common stock.
• Dr. Daniel L. Alkon, M.D., a former officer and director, entered into a consulting agreement with the Company.

Stakeholder Impact

• Shareholders: Potential for significant dilution from preferred stock conversion and warrant exercise. High risk/reward profile due to pivot to volatile crypto assets. Existing shareholders may see their ownership percentage decrease.
• Investors (new): Accredited investors gain exposure to a new strategic direction in AI crypto, with potential for high returns but also significant risk. Preferred stock holders have preferential rights and dividends.
• Employees: Significant management changes at the top, potentially signaling broader organizational shifts. The focus on a new business area may lead to changes in skill requirements and workforce composition.
• Customers/Suppliers: Unclear direct impact on existing customers/suppliers of the previous pharmaceutical business. New strategy may attract new partners in the crypto/AI space.
• Creditors: The $5.5 million cash minimum covenant and restrictions on indebtedness and liens provide some protection, but the high-risk nature of crypto assets could affect the company's overall financial stability.

Next Steps

• Closing of the private placement on June 10, 2025.
• Initial acquisition of $10 million in Bittensor TAO tokens as soon as practical.
• Seeking Nasdaq Stockholder Approval for the issuance of common stock exceeding 19.99% of outstanding shares at a meeting no later than September 1, 2025.
• Quarterly redemption payments for Series D Preferred Stock commencing on September 30, 2025.
• Development of a new corporate website.
• Intention to change the company name and ticker symbol.
• Continued efforts to acquire up to $100 million in TAO tokens.

Key Dates

Recommendation

Keywords

Synaptogenix, SNPX, Private Placement, Convertible Preferred Stock, Warrants, Cryptocurrency, Digital Asset Treasury, Bittensor TAO, AI Token, Artificial Intelligence, James Altucher, Corporate Strategy, Capital Raise, Executive Changes, Dilution, Nasdaq